2027 ICD-10-CM Diagnosis Code C53.0Malignant neoplasm of endocervix
ICD-10-CM Codes›C00–D49›C51-C58›C53
- Billable — Valid for Submission
- Risk Adjusts — HCC 22
- Chronic Condition
C53.0 is a billable ICD-10-CM diagnosis code for malignant neoplasm of endocervix. It is valid on HIPAA claims for fiscal year 2027 (October 1, 2026 through September 30, 2027) and groups to MS-DRG 731 through 733, 754 through 756. In AHRQ's Clinical Classifications Software (CCSR), this diagnosis falls under Female reproductive system cancers - cervix.
For Medicare Advantage risk adjustment, C53.0 maps to CMS-HCC Category 22 (Bladder, Colorectal, and Other Cancers) under the V28 model, adding a risk factor of about 0.363 for a community, non-dual, aged beneficiary in payment year 2027.
Code Identity
Code Classification
Medicare Risk Adjustment (HCC)Billing
C53.0 maps to a payment category in the CMS-HCC model used to risk-adjust Medicare Advantage payments. Weights are the published community factors for payment year 2027.
Source: CMS Payment Year 2027 risk adjustment mappings and model software. Weights are relative factors, not dollar amounts; a beneficiary's total RAF also includes demographics and interactions. Browse all CMS-HCC categories.
Approximate SynonymsGuidance
Alternate terms and clinical phrases that map to this code.
- Adenocarcinoma of cervix
- Carcinoma of cervix
- Carcinoma of endocervix
- Endocervical adenocarcinoma
- Malignant neoplasm of endocervical canal
- Malignant neoplasm of endocervical gland
- Malignant neoplasm of endocervix
- Primary adenocarcinoma of cervix uteri
- Primary adenocarcinoma of endocervix
- Primary carcinoma of cervix
- Primary carcinoma of endocervix
- Primary malignant neoplasm of endocervix
Instructional NotesGuidance
Instructions from the official ICD-10-CM Tabular List that apply to C53.0: its own notes plus those printed at C53, block C51-C58, and Chapter 2. A note printed at a category, block or chapter applies to every code under it.
Includes
Further defines, or gives examples of, the content of the category.
- malignant neoplasm of skin of female genital organs
Excludes1
Not coded here: the excluded code is never reported together with this one, unless the two conditions are unrelated.
Notes
General instructions on how these codes are used.
- Functional activity
- All neoplasms are classified in this chapter, whether they are functionally active or not. An additional code from Chapter 4 may be used, to identify functional activity associated with any neoplasm.
- Morphology [Histology]
- Chapter 2 classifies neoplasms primarily by site (topography), with broad groupings for behavior, malignant, in situ, benign, etc. The Table of Neoplasms should be used to identify the correct topography code. In a few cases, such as for malignant melanoma and certain neuroendocrine tumors, the morphology (histologic type) is included in the category and codes.
- Primary malignant neoplasms overlapping site boundaries
- A primary malignant neoplasm that overlaps two or more contiguous (next to each other) sites should be classified to the subcategory/code .8 ('overlapping lesion'), unless the combination is specifically indexed elsewhere. For multiple neoplasms of the same site that are not contiguous, such as tumors in different quadrants of the same breast, codes for each site should be assigned.
- Malignant neoplasm of ectopic tissue
- Malignant neoplasms of ectopic tissue are to be coded to the site mentioned, e.g., ectopic pancreatic malignant neoplasms are coded to pancreas, unspecified (C25.9).
Source: CMS ICD-10-CM Tabular List. How to read instructional notes.
Referenced in Other NotesGuidance
Instructional notes printed at other codes that name C53.0, its category, or a range that includes it.
Applicable To 2
These notes mention C53.0.
Clinical ClassificationClinical
AHRQ’s CCSR groups this code into broader clinical categories.
Clinical InformationClinical
Malignant Endocervical Neoplasm
a malignant neoplasm that affects the endocervix.
Table of NeoplasmsClinical
Anatomical sites in the Table of Neoplasms that reference this code family.
| Site | Malig. Primary | Malig. Secondary | Ca in situ | Benign | Uncertain | Unspec. |
|---|---|---|---|---|---|---|
| cervix (cervical) (uteri) (uterus) › canal | C53.0 | C79.82 | D06.0 | D26.0 | D39.0 | D49.59 |
| cervix (cervical) (uteri) (uterus) › endocervix (canal) (gland) | C53.0 | C79.82 | D06.0 | D26.0 | D39.0 | D49.59 |
| cervix (cervical) (uteri) (uterus) › internal os | C53.0 | C79.82 | D06.0 | D26.0 | D39.0 | D49.59 |
| cervix (cervical) (uteri) (uterus) › nabothian gland | C53.0 | C79.82 | D06.0 | D26.0 | D39.0 | D49.59 |
| endocervix (canal) (gland) | C53.0 | C79.82 | D06.0 | D26.0 | D39.0 | D49.59 |
| follicle, nabothian | C53.0 | C79.82 | D06.0 | D26.0 | D39.0 | D49.59 |
| internal › os (cervix) | C53.0 | C79.82 | D06.0 | D26.0 | D39.0 | D49.59 |
| nabothian gland (follicle) | C53.0 | C79.82 | D06.0 | D26.0 | D39.0 | D49.59 |
| os › internal | C53.0 | C79.82 | D06.0 | D26.0 | D39.0 | D49.59 |
| uterus, uteri, uterine › endocervix (canal) (gland) | C53.0 | C79.82 | D06.0 | D26.0 | D39.0 | D49.59 |
| uterus, uteri, uterine › internal os | C53.0 | C79.82 | D06.0 | D26.0 | D39.0 | D49.59 |
Patient EducationClinical
Cervical Cancer
Cervical cancer is cancer that starts in the cells of the cervix. The cervix is part of the female reproductive system. It is the lower, narrow end of the uterus (womb), which opens into the vagina (birth canal).
The full article covers:
- What is cervical cancer?
- What causes cervical cancer?
- Who is more likely to develop cervical cancer?
- What are the symptoms of cervical cancer?
- How is cervical cancer diagnosed?
- What are the treatments for cervical cancer?
- Can cervical cancer be prevented?
- What is Cervical Cancer?
Read the full article at MedlinePlus
Courtesy of MedlinePlus, a service of the U.S. National Library of Medicine.
Convert C53.0 to ICD-9-CMHistory
The closest ICD-9-CM equivalents under the General Equivalence Mappings.
Code HistoryHistory
Questions About C53.0Overview
What is the ICD-10 code for malignant neoplasm of endocervix?
The ICD-10-CM code for malignant neoplasm of endocervix is C53.0 (sometimes written as C530). It is billable on HIPAA-covered claims from October 1, 2026 through September 30, 2027.
Is C53.0 (Malignant neoplasm of cervix uteri) a billable code?
Yes. This is a billable ICD-10-CM code, specific enough to report malignant neoplasm of endocervix on HIPAA-covered claims from October 1, 2026 through September 30, 2027.
What MS-DRG does C53.0 group to?
When malignant neoplasm of endocervix is the principal diagnosis on an inpatient stay, it groups to MS-DRG 732, 755, 756, 754, 733, 731, with relative weights from 0.8583 to 3.5462 depending on complications. Higher weights mean higher Medicare reimbursement.
Can C53.0 be reported with a code from D06?
Not as a rule. The Excludes1 note at C53, which applies to C53.0, lists "carcinoma in situ of cervix uteri (D06.-)". An Excludes1 note means the excluded code is never reported together with this one; the only exception is when the two conditions are unrelated to each other (Official Guidelines, Section I.A.12.a).
What is the ICD-9 equivalent of C53.0?
Under the General Equivalence Mappings, malignant neoplasm of endocervix converts to ICD-9-CM 180.0 (malig neo endocervix). The mapping is a direct match.
What HCC is C53.0?
C53.0 (malignant neoplasm of endocervix) maps to CMS-HCC Category 22 (Bladder, Colorectal, and Other Cancers), commonly written as HCC 22, in the CMS-HCC V28 model used for Medicare Advantage risk adjustment in payment year 2027. It mapped to HCC 11 under the retired V24 model. It also maps in the PACE (CMS-HCC V22), ESRD (V21), and ESRD (V24) models. It does not map to any RxHCC in the Part D prescription drug model.
Does C53.0 risk-adjust for Medicare Advantage payment?
Yes. When documented and reported on a Medicare Advantage encounter, C53.0 adds a risk adjustment factor of about 0.363 to the beneficiary's RAF score for a community, non-dual, aged enrollee (published V28 weights range from 0.314 to 0.410 depending on the payment segment). A more severe related category (HCC 17, HCC 18, HCC 19, HCC 20, and HCC 21) supersedes it when both are reported. See the full factor table on the HCC 22 category page.
